Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated throughout 2023

Adverum Biotechnologies Reports Second Quarter 2022 Financial Results

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022.

Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference

- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years

Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

- Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.

Adverum (ADVM) Completes IND Amendment for Gene Therapy Study

American Rebel Holdings Inc

Kiromic Biopharma

Top penny stocks to watch this week. The post Top Penny Stocks To Buy Today?

Top Penny Stocks To Buy Today? 3 To Watch Under $3

Adverum Biotechnologies Inc (NASDAQ: ADVM) announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal injection for wet age-related macular degeneration (AMD). Adverum intends these.

Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022

- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the Phase 2 LUNA trial

Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD

REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration (wet AMD).  Adverum's lead gene therapy candidate, ADVM-022 is a one-time, intravitreal (IVT) injection for the treatment of patients with wet AMD.

Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD

- Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 in OPTIC study subjects with wet age-related macular degeneration (wet AMD)

Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD

- OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept) for wet AMD shows therapeutic levels of aflibercept out to three years - New evaluation of the impact of baseline levels of neutralizing antibodies (NAbs) to AAV.7m8 on ADVM-022 efficacy, safety and anatomical outcomes

Adverum Biotechnologies Announces New Data at the Macula Society's 2022 Annual Meeting

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today will announce new research pipeline data supporting the utility of its proprietary adeno-associated virus (AAV) vector platform in ocular gene therapy. These new data will be featured in oral presentations during the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting in Washington, D.C. and virtually.

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

- Human equivalent ADVM-022 dose of 6E10 vg/eye provided therapeutic levels of aflibercept in NHPs

Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022

REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2022.

Adverum Biotechnologies Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new data will be presented during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, being held May 16-19, 2022, in Washington D.C. and virtually.

Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022

- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81% in all patients to 94% in those with NAbs

Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting

Szilárd Kiss, M.D. to present new post-hoc analyses from the Phase 1 OPTIC Trial of ADVM-022 (AAV.7m8-aflibercept) in wet AMD Szilárd Kiss, M.D. to present new post-hoc analyses from the Phase 1 OPTIC Trial of ADVM-022 (AAV.7m8-aflibercept) in wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study

Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient in the planned Phase 2 trial during Third Quarter of 2022 Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient in the planned Phase 2 trial during Third Quarter of 2022

Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., as independent members of Adverum's Board of Directors. Dr. Ozden joins with two decades of experience in ophthalmology, clinical development and operations, pharmacovigilance, regulatory affairs and gene therapy. Ms. Hong brings a deep expertise in human capital management, executive and leadership development as well as executive and board compensation design and governance serving rapidly growing organizations during periods of transformation.

Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J.

Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Auditory and Ophthalmology panel discussion at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022, at 2:10 p.m. ET.

Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference

- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration -

Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Star Seyedkazemi, Pharm.D., joined Adverum as the company's chief development officer. Dr. Seyedkazemi will serve as a member of Adverum's executive committee and will report to Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. Dr. Seyedkazemi will provide leadership for the company's development programs, including global clinical operations, program strategy and project management.

News for Adverum Biotechnologies Stock (ADVM)